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Accepted 28 November 2017; Published online 5 December 2017AbstractObjective: We investigated the associations between risk of bias judgments from Cochrane reviews for sequence generation, allocation
concealment and blinding, and between-trial heterogeneity.
Study Design and Setting: Bayesian hierarchical models were fitted to binary data from 117 meta-analyses, to estimate the ratio l by
which heterogeneity changes for trials at high/unclear risk of bias compared with trials at low risk of bias. We estimated the proportion of
between-trial heterogeneity in each meta-analysis that could be explained by the bias associated with specific design characteristics.
Results: Univariable analyses showed that heterogeneity variances were, on average, increased among trials at high/unclear risk of bias
for sequence generation (bl 1.14, 95% interval: 0.57e2.30) and blinding (bl 1.74, 95% interval: 0.85e3.47). Trials at high/unclear risk of
bias for allocation concealment were on average less heterogeneous (bl 0.75, 95% interval: 0.35e1.61). Multivariable analyses showed that
a median of 37% (95% interval: 0e71%) heterogeneity variance could be explained by trials at high/unclear risk of bias for sequence gen-
eration, allocation concealment, and/or blinding. All 95% intervals for changes in heterogeneity were wide and included the null of no
difference.
Conclusion: Our interpretation of the results is limited by imprecise estimates. There is some indication that between-trial heteroge-
neity could be partially explained by reported design characteristics, and hence adjustment for bias could potentially improve accuracy of
meta-analysis results. Crown Copyright  2017 Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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1. Introduction the extent of between-study heterogeneity in a meta-analysisIn published meta-analyses, the original studies are often
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by/4.0/).[1,2]. This is likely to comprise a mixture of variation caused
by true diversity among the study designs, variation due to
within-study biases, and unexplained variation. For this
reason, it would be preferable to separate heterogeneity due
to bias from other sources of between-study variation, as
proposed by Higgins et al. [3].
Biases associated with reported study design characteris-
tics can be investigated within meta-epidemiological studies
that analyze a collection of meta-analyses. An early example
is that of Schulz et al. [4], where the methodological quality
of 250 randomized controlled trials from 33 meta-analyses
within the Cochrane Pregnancy and Childbirth database
was assessed. Schulz et al. provided empirical evidence to
suggest that trials in which randomization is inadequately
concealed report exaggerated estimates of intervention effectcess article under the CC BY license (http://creativecommons.org/licenses/
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Key findings
 Trials at high or unclear risk of bias for blinding or
sequence generation have, on average, higher
levels of heterogeneity variance than trials at low
risk of bias.
 There is little evidence that heterogeneity variance
can be explained by trials at high or unclear risk of
bias for allocation concealment.
 The extent of between-trial heterogeneity due to
reported design characteristics is very variable
across meta-analyses.
What this adds to what was known?
 Previous empirical studies have shown that the bias
associated with specific reported design character-
istics can lead to exaggerated intervention effect
estimates in randomized trials.
 The empirical evidence provided gives some
indication of the extent to which we might expect
heterogeneity variance to change, on average, if
we adjust for reported design characteristics in
meta-analysis. However, interpretation is limited
by very imprecise estimates.
What is the implication and what should change
now?
 We recommend an ‘‘all available evidence’’
approach to meta-analysis, together with adjustment
for known sources of bias. Adjustment for reported
design characteristics has potential to improve the
accuracy of meta-analysis results; in particular, pre-
diction intervals for true effects could be narrowed
if biases have been accounted for.
46 K.M. Rhodes et al. / Journal of Ccompared with adequately concealed trials. There was also
some indication that trials with inadequate blinding yield
larger effect estimates.
More recently, the Bias in Randomized and Observational
studies (BRANDO) study and Risk of Bias in Evidence Syn-
thesis (ROBES) study have investigated the associations be-
tween reported design characteristics and intervention effects
and heterogeneity [5,6]. The BRANDO study combined data
from all existing meta-epidemiological studies (collections of
meta-analyses) into a single database, comprising 1,973 inde-
pendent trials included in 234 meta-analyses. The ROBES
database included 228 binary outcome meta-analyses from
Cochrane reviews that had implemented the Cochrane risk
of bias tool [7]. In the BRANDO study, all trials included
in the database had been categorized according to whetherthey were judged as adequate, inadequate, or unclear for
sequence generation, allocation concealment, and double-
blinding. Trials included in the ROBES study database had
been categorized as being at high, low, or unclear risk of bias
for sequence generation, allocation concealment, blinding,
and incomplete outcome data, using the Cochrane risk of bias
tool. The results of both meta-epidemiological studies
showed that the relative intervention effect in favor of the
experimental treatment is, on average, modestly exaggerated
in trials with inadequate randomization and lack of blinding.
The ROBES study found no evidence of bias due to a high or
unclear risk of bias assessment for incomplete outcome data.
Both studies also found that bias in intervention effect
estimates associated with the lack of blinding in trials with
subjective outcome measures may be unpredictable in its
direction and magnitude, leading to increased within meta-
analysis heterogeneity.
When deciding how to handle suspected biases, meta-
analysts often consider whether to restrict their analyses to
studies at lower risk of bias or to include all available
evidence. Restricting analyses to studies at lower risk of bias
may lead to an unbiased result, but this result would be
imprecise if high-quality evidence is sparse. On the other
hand, combining all available studies and ignoring flaws in
their conduct could lead to biased summary estimates with
inappropriate clinical or policy decisions as a possible conse-
quence. Welton et al. [8] proposed a method for meta-
analysis that uses all available data, while adjusting for and
down-weighting the evidence from lower quality studies,
based on evidence from a meta-epidemiological study.
The analyses of BRANDO and ROBES followed
methods proposed by Welton et al. [8], which model the
effects of lower quality design characteristics on average
bias and between-trial heterogeneity. Under these models,
the trials judged to be of poorer quality were assumed to
be at least as heterogeneous as those of higher quality,
which may not be the case. We have since proposed
label-invariant models that avoid this constraint [9]. Our
models are more flexible than the models of Welton et al.
in allowing us to quantify the ratio by which heterogeneity
changes for studies with lower quality design characteris-
tics. This facilitates the investigation of how much
between-study heterogeneity in a meta-analysis is attribut-
able to lower quality studies.
Bias can lead to overestimation or underestimation of
the true intervention effect in a study, and we could expect
differences in risk of bias across studies to contribute to
variation among the results of studies included in a meta-
analysis. Here we reanalyze trial data from the ROBES
database, using our label-invariant models to investigate
the associations between risk of bias judgments from
Cochrane reviews and heterogeneity among randomized
controlled trials. We investigate the extent of heterogeneity
in a meta-analysis that is due to within-trial biases. The
empirical evidence provided gives useful information on
the extent to which we might expect the between-trial
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known sources of bias.
2. Methods
2.1. Data description
We make use of data from the ROBES [5] study, which is
a large collection of meta-analyses extracted from the
Cochrane Database of Systematic Reviews. These data were
originally used to examine the associations between reported
design characteristics and intervention effect estimates in
meta-analyses. Meta-analyses with fewer than five trials were
excluded, as were meta-analyses where the review authors
considered pooling to be inappropriate or where numerical
data were unavailable. One or more binary outcome meta-
analysis from each eligible review was included in the data-
base, corresponding to a primary outcome where possible.
The data set includes 228 meta-analyses from Cochrane re-
views that had information on all five of the following risk
of bias items: sequence generation, allocation concealment,
blinding, incomplete outcome data, and selective outcome
reporting. In this article we do not consider the influence of
accounting for bias caused by incomplete outcome data or
selective outcome reporting on heterogeneity. The ROBES
study found no evidence of exaggerated intervention effect
among trials at high or unclear risk of bias (compared with
low risk of bias) for assessment of incomplete outcome data
[5], and it is not generally recommended to try to adjust for
selective outcome reporting bias in meta-analysis [10].
Our statistical analyses were carried out on a subset of the
ROBES study, comprising 1,473 trials from 117 meta-
analyses. These meta-analyses contained at least one trial at
low risk of bias and at least one trial at high or unclear risk
of bias for each of the three characteristics of interest:
sequence generation, allocation concealment, and blinding.
Focusing on one subset of the data throughout all analyses
allowed for direct comparison of results assessing the influ-
ences of accounting for different combinations of study
design characteristics on heterogeneity. Table 1 shows the
structure of the data set. For each trial included in the ROBES
database, we have binary outcome data consisting of the
number of events in each treatment arm and the total number
of participants in each arm. The direction of outcome events
in the ROBES database is coded such that the outcome for
each trial corresponds to a harmful event. All meta-
analyses in the database have been categorized according
to the type of outcome under assessment and the types of in-
terventions evaluated, in the same way as Turner et al. [1].
Outcomes in the ROBES database were classified into three
broad categories (all-cause mortality, other objective, and
subjective) in the same way as the BRANDO study [6].
2.2. Statistical analysis
We used label-invariant hierarchical models to analyze
trial data from all included meta-analyses simultaneously.The models were fitted as described in an earlier article
[9] and are based on an extension of the model described
as ‘‘model 3’’ by Welton et al. [8]. Within each meta-
analysis, a model with binomial within-trial likelihoods
was fitted to the binary outcome data from each trial on
the log odds ratio scale. The model assumes that the higher
quality trials at low risk of bias provide an unbiased
estimate of intervention effect, assumed to have a normal
random-effects distribution with variance t2m specific to
each meta-analysis indexed m. Throughout our analyses,
we used a dichotomized variable for each design character-
istic (high or unclear risk of bias compared with low risk of
bias for sequence generation, allocation concealment, and
blinding). The trials at high or unclear risk of bias are
assumed to estimate the sum of two components: the same
intervention effect as the trials at low risk of bias plus some
trial-specific bias. Within each meta-analysis, we quantify
variation among trials at high or unclear risk of bias by
lt2m, which can be lower or higher than the variation t
2
m
among trials at low risk of bias. For each design character-
istic, the hierarchical models allow us to estimate the
following: the average bias in estimated intervention effect
within meta-analysis m (bm); the average bias in estimated
intervention effect across meta-analyses (b0); the ratio by
which between-trial heterogeneity in intervention effects
changes for trials with potential flaws (l); and variation
in average bias across meta-analyses (4).
We first conducted univariable analyses examining the
influence of accounting for a single trial design character-
istic on heterogeneity before carrying out multivariable
analyses examining the influence of accounting for all three
design characteristics. In multivariable analyses, interac-
tions between the different design characteristics were
assumed to have distinct variance components l and 4.
Following the approach of Turner et al. [1], we fitted a
log-normal model to the underlying values of heterogeneity
variance t2m in intervention effect among trials with low risk
of bias across meta-analyses. Previous research has shown
that the extent of total heterogeneity in a meta-analysis
differs according to the type of outcome examined in the
meta-analysis [1,2]. To investigate the association between
the type of outcome under assessment and the heterogene-
ity variance among trials with low risk of bias, we included
indicators for the different types of outcome as covariates in
the model for t2m.
All models were fitted using Markov chain Monte Carlo
(MC) methods within WinBUGS, version 1.4.3 [11].
We based our results on 100,000 iterations, after a
burn-in period of 10,000 iterations, which was sufficient
to achieve convergence and produced low MC error
rates. Convergence was assessed according to the
BrookseGelmaneRubin diagnostic tool [12], using two
chains starting from widely dispersed initial values. As in
our earlier article [9], we assigned normal (0, 1000) prior
distributions to location parameters and a log-normal
(0, 1) for l. Variation in average bias across
Table 1. Structure of the data set
N Min Median Max IQR
No. of trials per meta-analysis 117 meta-analyses 5 10 75 6e14
No. of participants per trial 1,473 trials 8 119 182,000 60e267
Abbreviations: N, frequency; IQR, inter-quartile range.
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0.001) prior with increased weight on small values. Model
fit was assessed using the deviance information criterion, as
recommended by Spiegelhalter et al. [13,14]. Due to the
nonlinearity between the likelihood and the model parame-
ters, we calculated the effective number of parameters at
the posterior mean of the fitted values rather than at the pos-
terior mean of the basic model parameters [15]. The Win-
BUGS code for fitting the label-invariant models is
available in the Supporting Information of an earlier article
[9].
2.3. Quantifying heterogeneity due to bias
It is of interest to quantify the proportion of between-trial
heterogeneity in a meta-analysis that can be explained by the
bias associated with reported design characteristics. This re-
quires an estimate of total heterogeneity variance among all
trials included in a meta-analysis and an estimate of the het-
erogeneity variance after accounting for biases. The latter is
estimated from the model above, where the three design
characteristics are assumed to be responsible for all of the
within-trial biases. In univariable analyses for the influence
of accounting for a single characteristic, we estimated total
heterogeneity variance t2total;m in a meta-analysis m, using
the formula t2m=ðð1 pmÞt2m þ pmlt2m þ pmð1 pmÞb2mÞ,
where pm is the proportion of trials at high or unclear risk
of bias in meta-analysis m. The derivation of this formula
for total heterogeneity variance is provided in
Supplementary material (S1), together with the formula used
in multivariable analyses for the influence of accounting for
two characteristics. We note that the formula used in
multivariable analyses for the influence of accounting for
three characteristics is derived in the same way. For each
meta-analysis m within the subset of 117 meta-analyses in
ROBES, we used WinBUGS to obtain the posterior median
for the ratio of between-trial variance among trials at high or
unclear risk of bias to total between-trial variance
1 t2m=t2total;m. For each individual design characteristic
and all combinations of design characteristics, we summa-
rize the proportion of heterogeneity attributable to trials at
high or unclear risk of bias by the median and 95% interval
of posterior medians for 1 t2m=t2total;m across meta-
analyses indexed m.
Negative estimates of the proportion of heterogeneity
due to trials at high or unclear risk of bias occur where
the estimate of total heterogeneity variance t2total among
all trials included in a meta-analysis is less than the esti-
mate of the heterogeneity variance t2 among trials at lowrisk of bias. We note that t2total is not only increased from
t2 by the heterogeneity variance among trials at high or
unclear risk of bias, but also the difference in intervention
effect between the trials at high or unclear risk of bias
and the trials at low risk of bias (see formula in
Supplementary material (S1)). We set the negative values
of the ratio to zero because total between-trial heterogene-
ity in the meta-analysis cannot be explained by the trials at
high or unclear risk of bias.
We graphically explored the influence of accounting for
reported design characteristics on heterogeneity on ran-
domized trials in meta-analysis. For each meta-analysis m
within the subset of ROBES, we plotted the posterior
median of heterogeneity variance t2m among trials at low
risk of bias against the posterior median of heterogeneity
variance t2total;m among all trials.3. Results
3.1. Descriptive analyses
Table 2 reports the number of trials with each combina-
tion of reported design characteristics. The frequency of
trials categorized as being at high or unclear risk of bias
for a single design characteristic was 303 (21%), of which
75 (25%) were at high or unclear risk of bias for sequence
generation, 98 (32%) were at high or unclear risk of bias
for allocation concealment, and 130 (43%) were at high
or unclear risk of bias for blinding. The number of trials
categorized as being at high or unclear risk of bias for pre-
cisely two design characteristics was somewhat higher at
413 (28%). All three design characteristics were judged
as high or unclear risk in 396 (27%) of trials. For each
design characteristic, Table 2 shows the breakdown of
the trial numbers into high risk of bias and unclear risk
of bias, overall and according to the type of outcome under
assessment. Of all 1,473 trials in the data set, sequence
generation was assessed as high risk of bias in 41 (3%) tri-
als, unclear in 736 (50%) trials, and low risk of bias in 696
(47%) trials. Allocation concealment was assessed as high
risk of bias in 80 (5%) trials, unclear in 760 (52%) trials,
and low risk of bias in 633 (43%) trials. Blinding was as-
sessed as high risk of bias in 317 (22%) trials, unclear in
383 (26%) trials, and low risk of bias in 773 (52%) trials.
The proportions of trials judged as being at high or unclear
risk of bias are greatest among trials with subjectively
measured outcomes and lowest among trials assessing
all-cause mortality.
Table 2. The overall number of trials with each combination of reported design characteristics, within the subset of 117 meta-analyses extracted
from the ROBES study, and the number of trials at high or unclear risk of bias for each reported design characteristics overall and according to
type of outcome measure
Risk of bias
No. of trials (%)
No. of trials at high risk of bias
(% of trials)
No. of trials at unclear risk of bias
(% of trials)
Sequence
generation
Allocation
concealment Blinding
Sequence
generation
Allocation
concealment Blinding
Sequence
generation
Allocation
concealment Blinding
Low Low Low 361 (25%) - - - - - -
High or unclear Low Low 75 (5%) 0 (0%) - - 75 (100%) - -
Low High or unclear Low 98 (7%) - 8 (8%) - - 90 (92%) -
Low Low High or unclear 130 (9%) - - 75 (58%) - - 55 (42%)
High or unclear High or unclear Low 239 (16%) 9 (4%) 8 (3%) - 230 (96%) 231 (97%) -
High or unclear Low High or unclear 67 (5%) 1 (1%) - 28 (42%) 66 (99%) - 39 (58%)
Low High or unclear High or unclear 107 (7%) - 19 (18%) 60 (56%) - 88 (82%) 47 (44%)
High or unclear High or unclear High or unclear 396 (27%) 31 (8%) 45 (11%) 154 (39%) 365 (92%) 351 (89%) 242 (61%)
Overall 1,473 (100%) 41 (3%) 80 (5%) 317 (22%) 736 (50%) 760 (42%) 383 (26%)
Mortality outcome 271 (18%) 7 (3%) 22 (8%) 76 (28%) 100 (37%) 104 (38%) 36 (13%)
Objective outcomea 301 (20%) 9 (3%) 13 (4%) 74 (25%) 145 (48%) 152 (51%) 54 (18%)
Subjective outcomeb 901 (61%) 25 (3%) 45 (5%) 167 (19%) 491 (55%) 504 (56%) 293 (33%)
Abbreviation: ROBES, Risk of Bias in Evidence Synthesis.
a Ten (37%) meta-analyses measured objective outcomes other than all-cause mortality including laboratory assessed outcomes, pregnancy,
and perinatal outcomes. Seventeen (62%) meta-analyses assessed objective outcomes potentially influenced by judgment such as caesarean sec-
tion and hospital admissions.
b Subjectively measured outcomes include pain, mental health outcomes, cause-specific mortality, clinically assessed outcomes, signs and
symptoms reflecting continuation/end of condition, and lifestyle outcomes.
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Results from model comparison are provided in
Supplementary material (S2). The multivariable model for
the influence of accounting for high or unclear risk of bias
for sequence generation and blinding (model B2) had an
improved fit when an interaction term was included. Howev-
er, after adjustment for trials at high or unclear risk of bias
for allocation concealment (model B4) there was no evi-
dence of interaction between sequence generation and blind-
ing. Despite this, we base our results on models including
interaction terms among reported design characteristics
because we would expect reported design characteristics to
interact in practice.
The inclusion of outcome type indicators in the model
for heterogeneity variance t2 did not lead to a substantial
improvement in model fit. For this reason, our results are
based on hierarchical models for t2 fitted without these
covariates.
3.3. Exploring the associations between reported trial
design characteristics and heterogeneity
Reported in Table 3 are estimates of l representing the
ratio by which heterogeneity variance changes for trials at
high or unclear risk of bias for specific design characteris-
tics, compared with trials at low risk of bias. Estimates of
average bias (b0) and variation in mean bias across meta-
analyses (4) were almost identical to those reported
elsewhere [5] and hence not reported here.
Each estimate of l in Table 3 is very imprecisely esti-
mated; the 95% credible intervals for l are wide and
contain the null value 1 representing no difference inheterogeneity among trials at high or unclear risk of bias
and trials at low risk of bias. For this reason we interpret
the results that follow with caution.
3.3.1. Univariable analyses
Based on univariable analyses for the influence of
accounting for a single reported design characteristic,
variation among trials at high or unclear risk of bias for
sequence generation is, on average, 14% greater than that
among trials at low risk of bias for sequence generation
(bl 1.14, 95% interval: 0.57e2.30). Heterogeneity among
trials judged as high or unclear risk of bias for allocation
concealment is, on average, 75% that among trials assessed
as low risk of bias for allocation concealment (bl 0.75, 95%
interval: 0.35e1.61). The central estimate for l suggests
that variation among trials at high or unclear risk of bias
for blinding is, on average, 74% greater than that among tri-
als at low risk of bias for blinding (bl 1.74, 95% interval:
0.85e3.47).
3.3.2. Multivariable analyses
Also reported in Table 3 are results from multivariable
analyses for the influence of accounting for combinations
of design characteristics. Based on results from fitting
model B1, heterogeneity among trials at high or unclear
risk of bias for both sequence generation and allocation
concealment is, on average, 94% that among trials at low
risk of bias for both sequence generation and allocation
concealment (bl 0.94, 95% interval: 0.39e1.90). Heteroge-
neity among trials at high or unclear risk of bias for both
sequence generation and blinding is, on average, 58%
greater than that among trials at low risk of bias for both
Table 3. Results from univariable and multivariable analyses for the influence of accounting for trials at high or unclear risk of bias for specific
design characteristics on heterogeneity. Posterior medians and 95% intervals are reported
Model Univariable analyses l
High or unclear risk (vs. low risk) of bias for
A1 Sequence generation 1.14 (0.57e2.30)
A2 Allocation concealment 0.75 (0.35e1.61)
A3 Blinding 1.74 (0.85e3.47)
Multivariable analyses (from models including interaction terms)a
High or unclear risk (vs. low risk) of bias for
B1 Sequence generation, in trials at low risk of bias for allocation concealment 0.76 (0.14e1.79)
Allocation concealment, in trials at low risk of bias for sequence generation 0.54 (0.10e1.41)
Sequence generation and allocation concealment 0.94 (0.39e1.90)
B2 Sequence generation, in trials at low risk of bias for blinding 0.59 (0.14e1.46)
Blinding, in trials at low risk of bias for sequence generation 1.01 (0.41e2.73)
Sequence generation and blinding 1.58 (0.59e4.65)
B3 Allocation concealment, in trials at low risk of bias for blinding 0.65 (0.20e2.14)
Blinding, in trials at low risk of bias for allocation concealment 1.69 (0.44e5.68)
Allocation concealment and blinding 1.41 (0.55e4.02)
B4 Sequence generation, in trials at low risk of bias for allocation concealment and blinding 0.46 (0.11e1.13)
Allocation concealment in trials at low risk of bias for sequence generation and blinding 0.49 (0.12e1.71)
Blinding, in trials at low risk of bias for sequence generation and allocation concealment 0.99 (0.43e2.31)
Sequence generation and allocation concealment, in trials at low risk of bias for blinding 0.39 (0.07e1.29)
Sequence generation and blinding, in trials at low risk of bias for allocation concealment 1.44 (0.34e5.34)
Allocation concealment and blinding, in trials at low risk of bias for sequence generation 0.50 (0.16e1.92)
Sequence generation, allocation concealment, and blinding 1.22 (0.39e3.01)
l ratio of heterogeneity variance among trials at high or unclear risk of bias to heterogeneity variance among trials at low risk of bias.
a Note that the results for multiple characteristics are not implied by the results for each individual bias domain in the multivariable analysis,
due to the presence of all possible interactions between bias domains.
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(bl 1.58, 95% interval: 0.59e4.65). Results from fitting
model B3 show that heterogeneity is, on average, 41%
greater among trials at high or unclear risk of bias for both
allocation concealment and blinding, compared with trials
at low risk of bias for both characteristics (bl 1.41, 95% in-
terval: 0.55e4.02). Results from multivariable analyses for
the influence of accounting for all three design characteris-
tics (model B4) imply that heterogeneity is, on average,
22% greater among trials at high or unclear risk of bias
(compared with low risk of bias) for all three reported
design characteristics (bl 1.22, 95% interval: 0.39e3.01).
As in univariable analyses, estimates of association be-
tween heterogeneity and reported design characteristics
are very uncertain; 95% credible intervals for l all contain
the null effect.3.4. Investigating the extent of heterogeneity due to
reported trial design characteristics
We investigate the extent to which one might expect
between-trial heterogeneity in a random-effects meta-analysis
to change, on average, if we adjust for potential bias attribut-
able to specific design characteristics in a new meta-analysis.
Table 4 summarizes posterior medians of the proportion
of total between-trial heterogeneity attributable to trials at
high or unclear risk of bias across the subset of 117
meta-analyses in ROBES.3.4.1. Univariable analyses
In univariable analyses for the influence of accounting for
a single reported design characteristic, central estimates for
the proportion of between-trial variance explained by trials
at high or unclear risk of bias for sequence generation have
a median of 30% (95% interval: 7e46%) across
meta-analyses (model A1). There is less evidence that
between-trial heterogeneity in a meta-analysis is attributable
to the bias associated with low or unclear quality for
allocation concealment; central estimates for the proportion
of heterogeneity among trials at high or unclear risk of bias
have a median of 6% (95% interval: 0e17%) across meta-
analyses (model A2). Across meta-analyses, central estimates
for the proportions of between-trial heterogeneity explained
by bias associated with trials at high or unclear risk of bias
for blinding have a median of 40% (95% interval: 8e56%)
based on fitting model A3.
For each of the 117 meta-analyses included within the
subset of ROBES, Fig. 1 presents a comparison of the
central estimate of heterogeneity variance among trials at
low risk of bias and the central estimate of heterogeneity
variance among all trials. In separate univariable analyses
for the influences of high or unclear risk of bias for
sequence generation and blinding, the central estimate of
heterogeneity variance among trials at low risk of bias
tends to be lower than the central estimate of heterogeneity
among all trials. In contrast, the central estimate of hetero-
geneity variance among trials at low risk of bias for
Table 4. Summaries of posterior medians for the proportion of heterogeneity due to trials at high or unclear risk of bias for each design characteristic
and combinations of design characteristics within the subset of 117 meta-analyses extracted from the ROBES study
Model Design characteristic/s
Proportion of heterogeneity due to trials at high or
unclear risk of bias for the design characteristic/sa
A1 Sequence generation Median 0.30; 95% interval: 0.07e0.46
A2 Allocation concealment Median 0.06; 95% interval: 0e0.17
A3 Blinding Median 0.40; 95% interval: 0.08e0.56
B1 Sequence generation and/or allocation concealment Median 0.19; 95% interval: 0e0.48
B2 Sequence generation and/or blinding Median 0.37; 95% interval: 0e0.57
B3 Allocation concealment and/or blinding Median 0.31; 95% interval: 0e0.51
B4 Sequence generation, allocation concealment, and/or blinding Median 0.37; 95% interval: 0e0.71
Abbreviation: ROBES, Risk of Bias in Evidence Synthesis.
a Negative estimates suggest that heterogeneity among trials in a meta-analysis cannot be explained by trials at high or unclear risk of bias and
were hence set to zero.
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all trials in 73 (62%) meta-analyses.
3.4.2. Multivariable analyses
Based on results from multivariable analyses for the in-
fluence of accounting for multiple reported design charac-
teristics, one might hypothesize that heterogeneity among
trials in meta-analyses within ROBES can be explained
by the bias associated with sequence generation and/or
allocation concealment (model B1); across meta-analysesFig. 1. For each of the 117 meta-analyses within the subset of the ROBES st
risk of bias plotted against the central estimate of heterogeneity variance am
results from univariable model A1 for sequence generation, univariable mo
and multivariable model B4 for sequence generation, allocation concealm
ROBES, Risk of Bias in Evidence Synthesis.within the subset of ROBES, central estimates for the pro-
portion of heterogeneity due to trials at high or unclear risk
of bias have a median of 19% (95% interval: 0e48%). Es-
timates of the proportion of heterogeneity due to trials at
high or unclear risk of bias due to sequence generation
and/or blinding have a median of 37% (95% interval:
0e57%) across meta-analyses (model B2). This median is
slightly lower at 31% (95% interval: 0e51%) for heteroge-
neity variance explained by bias associated with trials at
high or unclear risk of bias for allocation concealmentudy, the central estimate of heterogeneity variance among trials at low
ong all trials. Central estimates of heterogeneity variance are based on
del A2 for allocation concealment, univariable model A3 for blinding,
ent, and blinding. Solid lines indicate that estimates are identical.
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ROBES, central estimates for the proportion of between-
trial heterogeneity explained by bias associated with trials
at high or unclear risk of bias for sequence generation,
allocation concealment, and/or blinding have a median of
37% (95% interval: 0e71%) based on fitting model B4.
In multivariable analyses for the influence of accounting
for all three characteristics, the central estimate of hetero-
geneity variance among trials at low risk of bias for all
three characteristics is lower than the central estimate of
heterogeneity variance among all trials in the majority of
107 (91%) meta-analyses (Fig. 1).4. Discussion
Within-study biases can lead to overestimation or underes-
timation of the true intervention effect in a study and are
expected to contribute to between-study variation in meta-
analyses [5,6,16]. With access to a meta-epidemiological data
set including meta-analyses which have implemented the
Cochrane risk of bias tool, it was possible to explore the
extent to which accounting for suspected biases influences
levels of heterogeneity. We have investigated the impact of
risk of bias judgments from Cochrane reviews for sequence
generation, allocation concealment, and blinding on
between-trial heterogeneity, using data from 117 meta-
analyses included in the ROBES study. Between-trial
heterogeneity in intervention effect is a common problem
in meta-analysis. The results of this empirical study show that
roughly a third of between-trial heterogeneity might be ex-
plained by trial design characteristics, on average. Prediction
intervals are becoming increasingly widely used to provide a
predicted range for the true intervention effect in an individ-
ual study [3,17] and are useful in decision-making [18]. The
implications of our research are that prediction intervals for
true effects could be narrowed to account for biases, if they
are to represent genuine variation in true effects.
This empirical study builds on previous meta-
epidemiological studies [4e6] that have focused on the
influence of accounting for reported design characteristics
on intervention effect rather than between-trial heterogene-
ity. Recent meta-epidemiological studies have tended to use
the methods proposed by Welton et al. [8], which are less
general in that they constrain trials at high or unclear risk
of bias to be at least as heterogeneous as trials at low risk
of bias. We previously proposed a more general model
for the analysis of meta-epidemiological data [9]. In this
study, the advantage of using our model was that we could
estimate the quantity l, representing the ratio by which
heterogeneity changes for trials at high or unclear risk of
bias compared with trials at low risk of bias.
Random-effects meta-analysis may be appropriate when
between-study heterogeneity exists. However, in some
situations, studies differ substantially in quality so the
random-effects assumption may be inadequate. When
confronted with evidence of varying quality in practice,meta-analysts may decide to restrict their analyses to studies
at lower risk of bias. However, this would not be practical in
the typical situation where few studies are available to be
included in the meta-analysis. The results of our meta-
epidemiological study give some indication of increased
heterogeneity among studies with high or unclear risk of bias
judgments. These findings support recommendations to
adjust for bias in meta-analyses of evidence of varying qual-
ity. Methods are available to adjust for and down-weight
studies of lower quality in meta-analysis, using generic
data-based evidence or expert opinion informed by detailed
trial assessment [8,19]. Based on our findings, these methods
could be expected to reduce between-study variation in meta-
analyses. Since the between-study variance parameter would
be imprecisely estimated in many meta-analyses that only
contain a small number of studies, we recommend assigning
an informative prior distribution to this parameter, based on
empirical evidence from historical meta-analyses [1,2].
For each reported design characteristic and combinations
of design characteristics, we calculated the proportion of het-
erogeneity in each meta-analysis that could be explained by
trials at high or unclear risk of bias. Summaries of posterior
medians for these proportions across meta-analyses give
some indication of the reduction in between-trial heteroge-
neity we might expect to see in a meta-analysis, if we adjust
for the bias associated with each reported design character-
istic or combination of reported design characteristics. There
is empirical evidence to suggest that flaws in the random
sequence generation and lack of blinding may lead to
increased levels of heterogeneity among randomized
controlled trials, on average, but flawed methods of alloca-
tion concealment might have little impact. These findings
should be interpreted with caution due to the limited statis-
tical power to detect differences in heterogeneity between
higher and lower quality trials. In each analysis, the ratio
of heterogeneity variance l attributable to bias was very
imprecisely estimated. Although it would be expected for
l to be imprecisely estimated in a single meta-analysis, we
hoped to gain precision when estimating across the
collection of meta-analyses included in the ROBES data-
base; however, variability across meta-analyses was high.
In our analyses of the ROBES data, we wanted to allow
the data to dominate and used a vague log-normal (0,1)
prior distribution for the heterogeneity parameter l. How-
ever, given the small amount of information available on
l in the data set, there was a possibility that results could
have been sensitive to the choice of vague prior distribu-
tion. In an earlier article, we used the same data set in a
sensitivity analysis to compare the effects of five different
prior distributions for l [9]. Posterior estimates for the scale
parameter l were consistent among the different priors,
with similar medians, and overlapping credible intervals.
Heterogeneity among trials at low risk of bias could be
explained by clinical differences, for example, difference
in participants or in the dosage or timing of an intervention.
In each univariable and multivariable analysis, we did not
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among trials at low risk of bias and the type of outcome un-
der assessment in the meta-analysis. This might be explained
by the fact that the majority of the outcomes examined in the
meta-analyses included in our analyses were subjectively
measured. In future work, it would be of interest to explore
how the extent of between-trial heterogeneity due to bias
may depend on the type of outcome under assessment and
the types of interventions being compared.
Another limitation is the accuracy of reported design
characteristics which may not well represent how a trial
was actually conducted. Trials that are conducted well
could be poorly reported [20]. Hill et al. [21] investigated
discrepancies between published reports and actual conduct
of randomized clinical trials and found that sequence
generation and allocation concealment were reported as
unclear in more than 75% of studies where these two char-
acteristics were actually at low risk of bias. A more recent
study found that descriptions of blinding in trial protocols
and corresponding reports were often in agreement [22].
These investigations provide some insight as to why the
influences of accounting for high or unclear risk of bias
for sequence generation and high or unclear risk of bias
for allocation concealment on intervention effect and
between-trial variance are smaller, compared with the ef-
fects of high or unclear risk of bias for blinding. Ideally,
we would have investigated this further by separating trials
at unclear risk of bias from trials at high risk of bias and
comparing heterogeneity estimates between trials at high
risk of bias and trials at low or unclear risk of bias. Howev-
er, the data on trials at high risk of bias were sparse.
It is possible that our results were confounded by the in-
fluence of other types of biases that could not be accounted
for in our analyses. For example, there is empirical evidence
of bias in the results of meta-analyses due to publication bias
and selective reporting of outcomes arising from the lack of
inclusion of statistically non-significant results [23,24].
Methods to adjust for reporting biases are available, but it
would have been impractical to apply these methods to each
meta-analysis in our data set. Meta-analyses affected by
reporting biases would be expected to overestimate interven-
tion effect, and so the extent of heterogeneity that we
observed among trials in the ROBES database could be
higher than expected.
The ROBES data set was extracted from the April 2011
issue of the Cochrane Database of Systematic Reviews, for
which the risk of bias in trials may have been assessed
before 2011. As of early 2011, Cochrane review authors
have assessed risk of bias due to blinding of participants
and personnel separately from blinding of outcome asses-
sors. In the future, it would be of interest to investigate
separate influences of accounting for blinding of partici-
pants and personnel and blinding of outcome assessors on
intervention effect and between-trial heterogeneity, once
large collections of meta-analyses with such assessments
become available. It would also be of interest to investigatethe impact of bias on intervention effect and heterogeneity
in other types of meta-analyses; our analyses were conduct-
ed using binary outcome data from Cochrane reviews only.
These include a wide range of application areas but may not
be representative of all health-care meta-analyses, and so
the findings in this article may not be generalizable to
meta-analyses included in other systematic reviews.
In conclusion, the overall implications of this research
are that the accuracy of meta-analysis results could be
improved by adjusting for reported study design character-
istics in the meta-analysis model. After conducting a
random-effects meta-analysis, it is important to consider
the potential effect of the intervention when it is applied
within an individual study setting because this might be
different from the average effect. In the presence of sub-
stantial heterogeneity among studies, prediction intervals
for the true intervention effect in an individual study will
be wide and uncertain. This empirical study gives some
indication that adjustment for bias could reduce the
uncertainty in predictive inferences and better reflect the
potential effectiveness of the intervention. A strategy of
including all studies with such adjustments may produce
a more favorable trade-off between bias and precision than
excluding studies assessed to be at high risk of bias. How-
ever, interpretation of our results is limited by extremely
imprecise estimates.Acknowledgments
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